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Summary
Background: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ul-
cerative colitis (UC).
Aim: To evaluate effectiveness, safety and use of tofacitinib in daily practice.
Methods: UC patients initiating tofacitinib were prospectively enrolled in 15 hospi-
tals in the Netherlands. Corticosteroid-free clinical remission (short clinical colitis ac-
tivity index [SCCAI] ≤2), biochemical remission (faecal calprotectin level ≤250 µg/g), 
combined corticosteroid-free clinical and biochemical remission, predictors of remis-
sion, safety outcomes, treatment dose and effect on lipids were determined at weeks 
12 and 24. Endoscopic outcomes were evaluated in centres with routine endoscopic 
evaluation.
Results: In total, 123 UC patients (95% anti-TNF, 62% vedolizumab and 3% usteki-
numab experienced) were followed for a median duration of 24 weeks (interquartile 
range 12-26). The proportion of patients in corticosteroid-free clinical, biochemical, 
and combined corticosteroid-free clinical and biochemical remission rate at week 24 
was 29% (n: 22/77), 25% (n: 14/57), and 19% (n: 11/57) respectively. Endoscopic re-
mission (Mayo = 0) was achieved in 21% of patients at week 12 (n: 7/33). Prior ved-
olizumab exposure was associated with reduced clinical remission (odds ratio 0.33, 
95% confidence interval [CI] 0.11-0.94). At week 24, 33% (n: 14/42) of patients still 
on tofacitinib treatment used 10 mg twice daily. In total, 33 tofacitinib-related ad-
verse events (89 per 100 patient years) occurred, 7 (6% of total cohort) resulted in 
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1  | INTRODUC TION
Tofacitinib is registered as an oral treatment option for ulcerative 
colitis (UC) in the Netherlands since the approval by the European 
Medicines Agency (EMA) in October 2018. It is a small-molecule 
Janus kinase (JAK) inhibitor which interferes with the intracellular 
JAK/signal transducer and activators of transcription (STAT) path-
way. This pathway plays an important role in the signal transduction 
of multiple pro-inflammatory cytokines involved in the pathogenesis 
of a spectrum of inflammatory diseases.1,2 The pivotal phase 3 clin-
ical OCTAVE trial demonstrated dose-dependent efficacy in induc-
ing and maintaining clinical remission in patients with moderately to 
severely active UC.3 However, due to strict inclusion and exclusion 
criteria, the study population does not accurately reflect the actual 
patient population receiving tofacitinib in regular care.4 For exam-
ple, in real-life setting, novel treatments are generally prescribed 
for patients who previously failed not only anti-TNF but also newer 
therapies such as vedolizumab. Moreover, trial protocols demand 
wash-out periods of prior therapies, stable therapy dose and strict 
pre-specified follow-up, which do not reflect routine care. Different 
treatment strategies can be adopted beyond trial protocols including 
dose optimisation and the addition of concomitant medication.
To date, only two cohort studies are available that describe the use 
of tofacitinib in daily practice.5,6 However, these cohorts are limited 
by the small population size and their retrospective nature. Using the 
Dutch Initiative on Crohn and Colitis (ICC) Registry, a prospective, nation-
wide, observational registry for novel IBD therapies, we aimed to deter-
mine real-world effectiveness, safety and the use of tofacitinib for UC.
2  | METHODS
2.1 | Study design and setting
The ICC Registry is a prospective, nationwide and observational 
registry of inflammatory bowel disease (IBD) patients initiating 
pre-specified IBD therapies in everyday care in the Netherlands. 
The design and rationale have previously been described in detail.7,8 
In short, IBD patients aged 16 years or older are included in eight 
university and seven non-university hospitals. The patients are fol-
lowed for 2 years with planned visits at initiation of therapy (base-
line) and during maintenance therapy (at weeks 12, 24, 52 and 104 or 
until medication is discontinued). Data are captured using electronic 
case report forms (eCRF) with automated reminders to ensure ad-
herence to the protocol.
2.2 | Participants
After formal approval of the regulatory authorities (October 
2018), all UC patients who started tofacitinib treatment in regular 
care at the participating centres were consecutively enrolled until 
November 2019. The decision to start therapy was at the discretion 
of the treating physician and there were no exclusion criteria other 
than mentioned in the summary of product characteristics for tofaci-
tinib. Tofacitinib was administrated according to label with an induc-
tion regimen of 10 mg twice daily for the first 8 weeks, followed by 
maintenance treatment of 5 mg twice daily with optional dose op-
timisation in case of insufficient response. Patients with combined 
clinical (short clinical colitis activity index [SCCAI] >2) and objective 
(endoscopy [Mayo ≥1] or biochemical (C-reactive protein, [CRP] con-
centration >5 mg/L or faecal calprotectin [FCP] level >250 µg/g)) 
disease activity at baseline were included to determine the effec-
tiveness outcomes. Data of all enrolled patients, independent of dis-
ease activity scores at baseline, were used to determine safety and 
usage outcomes.
2.3 | Outcomes and definitions
The primary outcome was the proportion of patients in corticos-
teroid-free clinical remission (SCCAI ≤2) at week 24. Secondary 
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discontinuation. Cholesterol, HDL and LDL levels increased during induction treat-
ment by 18% (95% CI 9-26), 18% (95% CI 8-28) and 21% (95% CI 14-39) respectively.
Conclusion: Tofacitinib is an effective treatment for UC after anti-TNF and vedoli-
zumab failure. However, a relatively high rate of adverse events was observed result-
ing in discontinuation in 6% of patients.
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outcomes included: clinical response (decrease in SCCAI ≥3 com-
pared with baseline), clinical remission (SCCAI ≤2), biochemical 
remission (FCP level ≤250 µg/g), combined corticosteroid-free 
clinical and biochemical remission, endoscopic remission (en-
doscopic Mayo score = 0) and endoscopic response (decrease 
in endoscopic Mayo score of ≥1 compared with baseline), and 
predictors of corticosteroid-free clinical remission. Changes in 
lipid concentrations, safety (possibly or probably related adverse 
events, adverse events requiring treatment discontinuation, mild 
infections: no antibiotics or anti-viral medication, moderate in-
fections: oral antibiotics or anti-viral medication or severe infec-
tions: hospitalisation or intravenously administrated antibiotics 
or anti-viral medication), treatment dose and drug survival were 
assessed.
Follow-up time was defined as time between the date of the 
first dosing and the last visit used in the analysis. Patients who dis-
continued tofacitinib due to primary or secondary nonresponse, 
adverse events or at their own request were considered treatment 
failures and classified as nonresponders in the remaining visits when 
follow-up would have been adequate. Patients who discontinued 
tofacitinib due to pregnancy were considered censored cases and 
were not included in the subsequent analysis. To limit bias, only the 
endoscopic outcomes of patients treated in centres with systematic 
endoscopic evaluation regardless of clinical and biochemical param-
eters were used in the analysis.
2.4 | Statistical methods
All analyses were performed on an intention-to-treat basis. 
Continuous variables were presented as means with standard de-
viations (SD) or as medians with interquartile ranges (IQR) depend-
ing on the normality of the underlying distribution. Continuous 
variables were subsequently compared using paired sample T test, 
independent T test or Mann-Whitney U test. Categorical variables 
were presented as percentages and compared using the Chi-square 
test. Cumulative drug survival was assessed using the Kaplan-Meier 
method. We explored predictors of corticosteroid-free clinical re-
mission at week 24 using a binary logistic regression. Due to the lim-
ited number of patients achieving this outcome, we a priori agreed 
on predictors associated with disease severity or refractory to test 
univariable. Variables with a P value of <0.2 in the univariable analy-
sis were selected for the multivariable analysis. A two-sided P value 
of 0.05 or less was considered statistically significant. All analyses 
were performed using IBM SPSS statistics for Windows, version 
24.0 (IBM Corp.).
2.5 | Ethical consideration
This study was reviewed and approved by the Committee on 
Research Involving Human Subjects at the Radboudumc (institu-
tional review board: 4076).
TA B L E  1   Baseline characteristics of ulcerative colitis patients 
initiating tofacitinib therapy
Baseline characteristics  UC (N = 123)
Agea  Median (IQR) 46.4 (32.9-55.7)
Gender—male N (%) 72 (58.5)
Body mass indexa  Mean (SD) 24.8 (4.2)
Current smoker N (%) 6 (4.9)
Disease duration in years Median (IQR) 7.6 (3.7-14.8)
Follow-up duration Median (IQR) 24.0 (12.0-25.7)
UC disease locationb 
Proctitis N (%) 11 (8.9)
Left sided N (%) 47 (38.5)
Pancolitis N (%) 63 (51.6)
Prior anti-TNF therapy use
≥1 N (%) 116 (95.1)
≥2 N (%) 48 (39.1)
3 N (%) 5 (4.1)
Unknown N (%) 1 (0.8)
Prior vedolizumab use N (%) 76 (62.3)
Prior vedolizumab and anti-TNF 
use
 73 (59.3)
Prior ustekinumab use N (%) 4 (3.3)
Clinical and biochemical disease activitya 
SCCAI Median (IQR) 8 (5-10)
CRP, mg/L Median (IQR) 5 (2-13)
Faecal calprotectin, µg/g Median (IQR) 1730 (550-2604)
Endoscopic disease activity (performed in 86 patients)
Mayo 1 N (%) 10 (10.9)
Mayo 2 N (%) 29 (31.5)
Mayo 3 N (%) 51 (55.4)
Unknown N (%) 2 (2.3)
Concomitant medication
No concomitant medication N (%) 71 (57.7)
Systemic corticosteroids N (%) 44 (35.8)
Corticosteroids range mg (IQR) 20 (15-30)
Immunosuppressants N (%) 6 (4.9)
Both systemic corticosteroids and 
immunosuppressants
N (%) 1 (0.8)
Corticosteroids range mg (IQR) 25
Unknown N (%) 1 (0.8)
Lipidsa 
Triglycerides—mmol/L (n: 65) Mean (SD) 1.52 (0.75)
Cholesterol—mmol/L (n: 71) Mean (SD) 4.65 (1.03)
High-density lipoprotein (HDL)—
mmol/L (n: 69)
Mean (SD) 1.42 (0.48)
Low-density lipoprotein (LDL)—
mmol/L (n: 65)
Mean (SD) 2.80 (0.85)
Abbreviations: anti-TNF, anti-tumour necrosis factor; CRP, C-reactive 
protein; immunosuppressants, thiopurines or methotrexate; IQR, 
interquartile range; N, number; SCCAI, short clinical colitis activity 
index.
aAt inclusion. 
bMaximum extent until inclusion. 
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3  | RESULTS
3.1 | Baseline characteristics
Baseline characteristics are displayed in Table 1. In total, 123 pa-
tients (118 UC and 5 IBD unclassified) were included. Patients were 
followed for a median duration of 24.0 weeks (IQR: 12.0-25.7) and 
were predominately men (58.5%) with a median disease duration of 
7.6 years (IQR: 3.7-14.8). At inclusion, 51.6% of patients had a pan-
colitis, 38.5% left-sided disease, and 8.9% had a proctitis. Prior to 
initiating tofacitinib treatment, 95.1% had previously been exposed 
to 1 or more anti-TNF drugs, 62.3% to vedolizumab and 59.3% to 
both anti-TNF and vedolizumab treatment while 3.3% had previ-
ously been exposed to ustekinumab. At baseline 41.5% received 
systemic corticosteroids, immunosuppressants or both (35.8% cor-
ticosteroids, 4.9% immunosuppressants (thiopurines or methotrex-
ate) and 0.8% both corticosteroids and an immunosuppressant).
Effectiveness outcomes were assessed in 111 patients who 
had both clinical and objective disease activity at baseline. These 
patients had a median SCCAI of 8 (IQR: 5-11), a median FCP level 
of 1800 µg/g (IQR: 633-2682) and a median CRP concentration of 
6 mg/L (IQR: 2-14). Eighty-six patients underwent endoscopic eval-
uation at baseline and the majority of patients had an endoscopic 
Mayo score of 3 (57.0%) (Mayo 1:9.3%, Mayo 2:31.4%).
3.2 | Clinical effectiveness
The proportion of patients in corticosteroid-free clinical remission at 
weeks 12 and 24 was 35.4% (n: 35/99) and 28.6% (n: 22/77) respec-
tively (Figure 1). The proportion of patients without prior exposure 
to vedolizumab showed significantly better results at week 12 (ved-
olizumab naïve: 47.4% (n: 18/38) vs vedolizumab exposed: 26.7% (n: 
16/60), P = 0.036) and at week 24 (44.4% (n: 12/27) vs 20.4% (n: 10/49), 
P = 0.027). A smaller proportion of patients without prior exposure to 
vedolizumab had a pancolitis at inclusion when compared to patients 
with exposure to vedolizumab (41.9% vs 56.7%, P = 0.017), while other 
baseline variables including clinical, biochemical and endoscopic dis-
ease activity were comparable (P = 0.763, 0.354, 0.663) at baseline.
The proportion of patients with clinical response at weeks 12 
and 24 was 55.6% (n:55/99) and 45.5% (n: 35/77) respectively. The 
proportion of patients in clinical remission at weeks 12 and 24 was 
41.4% (n: 41/99) and 32.5% (n: 25/77) respectively.
3.3 | Biochemical disease activity
The proportion of patients in biochemical remission (FCP 
≤250 µg/g) at weeks 12 and 24 was 37.0% (n: 30/81) and 24.6% 
(n: 14/57) respectively (Figure 2). Imputing missing FCP data as 
nonresponder, the biochemical remission rates at weeks 12 and 
24 were 30.3% (n: 30/99) and 18.2% (n: 14/77) respectively. The 
median FCP level of patients treated with tofacitinib at weeks 0, 
12 and 24 was 1800 µg/g (IQR: 633-2682), 143 µg/g (IQR: 32-871) 
and 230 µg/g (IQR: 39-984) respectively. The median CRP concen-
tration of patients treated with tofacitinib at weeks 0, 12, and 24 
was as follows: 6 mg/L (IQR: 2-14), 1 mg/L (IQR: 0-6) and 2 mg/L 
(IQR: 0-4) respectively.
3.4 | Combined clinical and biochemical remission
The proportion of patients in combined corticosteroid-free clinical 
and biochemical remission at weeks 12 and 24 was 28.4% (n: 23/81) 
and 19.3% (n: 11/57) respectively (Figure 2).
3.5 | Endoscopic outcomes
Three participating centres systematically scheduled endoscopies, 
independent of clinical and biochemical outcomes. In these cen-
tres, 33 patients underwent endoscopic evaluation after a median 
F I G U R E  1   Proportion of ulcerative colitis patients with clinical 
response (SCCAI decrease of ≥3 compared with baseline), clinical 
remission (SCCAI ≤2) and corticosteroid-free clinical remission at 
week 12 and 24. SCCAI, short clinical colitis activity index
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treatment duration of 9.9 weeks (IQR: 7.6-11.4). Endoscopic remis-
sion (endoscopic Mayo score 0) was achieved in 21.2% (n: 7/33) 
and endoscopic response was obtained in 36.4% (n: 12/33).
3.6 | Clinical factors associated with corticosteroid-
free clinical remission
Univariable and multivariable predictors of corticosteroid-free clinical 
remission at week 24 are depicted in Table 2. Prior exposure to vedoli-
zumab and SCCAI per point were associated with a reduced corticos-
teroid-free clinical remission rate at week 24 in multivariable analysis 
(OR: 0.301 95% CI: 0.100-0.907, P = 0.033, and OR: 0.825 95% CI: 
0.686-0.992, P = 0.041, respectively). Prior exposure to anti-TNF or 
ustekinumab treatment could not be assessed due to the small number 
of patients without previous anti-TNF or with ustekinumab treatment.
3.7 | Safety profile
The 123 patients included in the safety analysis were followed for a 
total of 37.0 patient years (Table 3). During follow-up, 7 (5.7%) patients 
discontinued tofacitinib due to adverse events, of whom 4 (57.1%) 
were treated with 10 mg twice daily while the other 3 received 5 mg 
twice daily at the time of treatment discontinuation. Twenty-three 
possibly (62.2 per 100 patient years) and three probably (8.1 per 100 
patient years) tofacitinib-related adverse events were encountered, 
of which cutaneous lesions and headache were the most common. A 
10 mg twice daily dose at week 12 was not associated with adverse 
events during follow-up (OR: 0.971, 95% CI: 0.740-1.275, P = 0.834). 
Thromboembolic events were not reported during this study. There 
were eight mild (21.6 per 100 patient years) infections and eight mod-
erate (21.6 per 100 patient years) infections but no severe infections 
during follow-up (Table 3). Four herpes zoster infections/reactivations 
 
Univariable analyses Multivariable analyses
OR 95% CI P value OR 95% CI P value
Age at inclusion—per 
year
1.040 0.999-1.082 0.057 1.041 0.997-1.088 0.069
BMI per pointa  1.057 0.934-1.197 0.381    
Gender
Male ref      
Female 1.391 0.516-3.755 0.514    
Disease duration—per 
year
1.015 0.955-1.078 0.636    
Disease location UCb   0.801    
Proctitis 0.000 0.000-0.000 0.999    
Left sided 1.409 0.515-3.855 0.505    
Pancolitis ref      
Prior biological treatments
≥2 anti-TNF  
agents
0.484 0.165-1.425 0.188 0.489 0.151-1.587 0.234
Vedolizumab 0.321 0.115-0.897 0.030 0.327 0.100-0.907 0.033
Clinical disease activity
SCCAI per point 0.865 0.734-1.020 0.084 0.825 0.686-0.992 0.041
Biochemical disease activity
CRP per mg/L 0.994 0.976-1.012 0.522    
FCP per  
100 µg/g
1.008 0.989-1.028 0.425    
Concomitant medication
Corticosteroids 1.038 0.379-2.842 0.941    
Note: A priori chosen variables with a P value of < 0.2 were selected for multivariable analysis, in 
which consequently a two-sided P value of ≤ 0.05 was considered statistically significant.
Abbreviations: anti-TNF, anti-tumour necrosis factor; BMI, body mass index; CRP, C-reactive 
protein; FCP, faecal calprotectin; OR, odds ratio; SCCAI, short clinical colitis activity index; ref, 
reference; 95% CI, 95% confidence interval.
aAt inclusion. 
bMaximum extent until inclusion. 
TA B L E  2   Clinical parameters 
associated with corticosteroid-free clinical 
remission in tofacitinib-treated ulcerative 
colitis patients at week 24 were tested by 
binary logistic regression model
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were reported. Fifteen hospitalisations (40.5 per 100 patient years) all 
due to disease worsening occurred during follow-up. Six patients un-
derwent a colectomy (16.2 per 100 patient years).
3.8 | Changes in lipid concentrations
The mean relative difference between baseline and after induction 
therapy for triglycerides (n:42), cholesterol (n:45), HDL cholesterol 
(n:44) and LDL cholesterol (n:44) levels was as follows: −4.4% (95% 
CI: −16.9%-8.1%, P = 0.246), 15.7% (95% CI: 8.0%-23.3%, P < 0.001), 
17.7% (95% CI: 6.9%-28.5%, P = 0.015) and 21.2% (95% CI: 10.5%-
32.0%, P = 0.001) respectively.
3.9 | Tofacitinib dose
Two patients were started on tofacitinib 5 mg twice daily (patient 
1: smoker with hypertension, arrhythmia, valvular heart disease, al-
cohol and drug abuse and axial spondyloarthritis, patient 2: hyper-
cholesterolemia and hypertension), all others used the registered 
induction regimen of 10 mg twice daily. At week 12 and week 24, 
43.1% (n: 31/72) and 33.3% (n: 14/42) of patients used 10 mg twice 
daily respectively. Of the patients who discontinued tofacitinib, 
76.1% (n: 35/46) used 10 mg twice daily, 21.7% (n: 10/46) used 5 mg 
twice daily and 2.2% (n: 1/46) used 15 mg twice daily.
3.10 | Drug survival
Cumulative tofacitinib drug survival is depicted in Figure 2. After 
24 weeks of follow-up, 60% of patients remained on tofacitinib 
(Figure 3). Of the patients who discontinued treatment, the median 
treatment duration was 8.5 weeks (IQR: 6.1-13.5). Main reasons for 
treatment discontinuation were lack of response (76.1%) and ad-
verse events (15.2%) (Table 4).
4  | DISCUSSION
We assessed the real-world effectiveness, safety and drug use of tofac-
itinib in the nationwide prospective Dutch ICC Registry. In this anti-TNF 
TA B L E  3   Number and details of adverse events during 
treatment of ulcerative colitis patients with tofacitinib
Possibly related 23 (62.2 per 100 patient 
years)
Cutaneous lesions 7  
Headache 5  
Oedema 2  
Hypertension 1  
Dyspnoea 1  
Insomnia 1  
Arthralgia 1  
Glaucoma 1  
Mood swings 1  
Galactorrhoea 1  
Cold sensation 1  
Itch 1  
Probably related 3 (8.1 per 100 patient years)
Headache 2  
Cutaneous lesions 1  
Adverse event as reason for 
discontinuation
7 (18.9 per 100 patient years)
Recurrent infections 2  
Hepatitis 1  
Globus 1  
Arthralgia 1  
Nausea 1  
Herpes zoster 1  
Mild infections 8 (21.6 per 100 patient years)
Fever (no focus) 3  
Flu-like symptoms 3  
Upper respiratory 1  
Herpes zoster 1  
Moderate infections 8 (21.6 per 100 patient years)
Urinary tract 3  
Herpes zoster 2  
Gastrointestinal 1  
Eye infection 1  
Fever (no focus) 1  
Severe infections  
—   
Hospitalisations 15 (40.5 per 100 patient 
years)
Note: Infections were classified as: mild infections: no antibiotics or 
anti-viral medication; moderate infections: oral antibiotics or anti-
viral medication; severe infections: hospitalisation or intravenously 
administrated antibiotics or anti-viral medication.
F I G U R E  3   Cumulative tofacitinib drug survival in ulcerative 
colitis patients after 24 wks of follow-up
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and vedolizumab refractory cohort, the corticosteroid-free clinical re-
mission rates at weeks 12 and 24 were 35% and 29% respectively. The 
number of adverse events (89 per 100 patient years) in general and 
as reason for discontinuation (6%) was relative high. The highest dose 
(10 mg twice daily) was prescribed in one-third of patients at week 24.
The results of our study show a discrepancy with the clinical trials 
(OCTAVE) in terms of the decline in effectiveness outcomes over time. 
Several factors may contribute to this observation, including the rela-
tive shorter duration of follow-up, the intention-to-treat design as well 
as corticosteroid taper for a subgroup of patients during follow-up. 
Indeed, other real-life cohort confirmed this finding (week 8 clinical re-
mission 33%, week 26:25%).5 To date, only two real-world retrospec-
tive cohorts have reported the effectiveness and safety of patients 
receiving tofacitinib before market authorisation. A single-centre co-
hort study reported 58 patients (93% anti-TNF and 81% vedolizumab 
exposed) treated with tofacitinib. After 26 weeks of treatment, 21% 
was in corticosteroid-free clinical remission (physician global assess-
ment).5 In a compassionate early-access programme in France, 38 
patients received tofacitinib after failure of both anti-TNF and vedol-
izumab treatment. In this treatment-refractory cohort, corticoste-
roid-free clinical remission (partial Mayo <3) at week 24 was 32%.6 The 
comparison with cohorts receiving treatment before market authori-
sation is difficult and outcomes should be interpreted cautiously due 
to the retrospective nature and different endpoints as compared with 
our systematic and prospective cohort with pre-defined endpoints.
With 89 treatment-related adverse events per 100 patient 
years, the rate of adverse events in tofacitinib-treated patients was 
relatively high when compared with other treatments given to an-
ti-TNF exposed patients.7,8 A recent review of clinical trials showed 
a comparable safety profile of tofacitinib when compared with 
vedolizumab and anti-TNF with the exception of herpes zoster in-
fections/reactivations.9 Another systematic review of clinical trials 
showed no increased risk of adverse events when JAK inhibitors 
were compared with placebo.10 However, in these reviews, not the 
number of adverse events but the number of patients with adverse 
events was compared. We were able to compare the real-world total 
number of tofacitinib-related adverse events with other treatments 
prescribed to anti-TNF refractory patients such as vedolizumab (in-
flammatory bowel disease [IBD]) and ustekinumab (Crohn's disease 
[CD]) following an identical methodology from our ICC Registry. This 
comparison yielded 30 treatment-related adverse events per 100 pa-
tient years for vedolizumab,8 24 treatment-related adverse events 
per 100 patient years for ustekinumab7 and 89 treatment-related 
adverse events per 100 patient years for tofacitinib, suggesting a 
less desirable profile in terms of adverse events for the latter. The 
rate of infections was relative low with no severe infections and 43 
mild-to-moderate infections per 100 patient years including 4 her-
pes zoster reactivations. The rate of infections was comparable with 
vedolizumab (IBD: 38 per 100 patient years)8 and ustekinumab (CD: 
36 per 100 patient years).7 However, the limited follow-up period 
could have biased these results as JAK inhibitors are associated with 
an increased risk of infections when compared with placebo (RR 1.40 
[95% CI 1.18-1.67], P < 0.0001).10 
In the first half of 2019, the FDA and EMA issued new safety 
warnings about an increased risk of venous thromboembolic events 
and related death, following the results of the ORAL Surveillance 
study in rheumatoid arthritis. In this study, patients aged >50 years 
with at least one additional cardiovascular risk factor, used tofaci-
tinib 10 mg twice daily as maintenance therapy.11 In our cohort 
one-third of patients at week 24 received 10 mg twice daily while 
no thromboembolic events were reported. However, our follow-up 
period (median follow-up of 24 weeks [IQR: 12-26]) might be too 
short to detect a potential increased risk for thromboembolic or 
cardiovascular events. In the OCTAVE studies, no significant differ-
ence was found with regard to efficacy in 5 or 10 mg twice daily 
during the maintenance study in induction responders.3 However, in 
the OCTAVE trial only 50% of patients was anti-TNF exposed and 
none of these patients received prior treatment with vedolizumab. 
Our real-world study represents a more therapy-refractory patient 
population, including partial induction responders who are possibly 
in need of a higher maintenance dose. Furthermore, physicians might 
prefer a higher maintenance dose due to the limited alternative ther-
apeutic options remaining. The OCTAVE open programme showed 
a recapture of response rate of 64.9% (37/57) after dose escalation, 
indicating that dose escalation could be an option for secondary non-
responders before switching out of class.12 Receiving 10 mg twice 
daily at week 12 was not associated with adverse events, however, 
cohorts with longer follow-up are needed to determine this effect.
A 16%-21% increase in serum lipid levels after tofacitinib induc-
tion therapy has been observed in this cohort, comparable to the re-
sults of tofacitinib clinical trials in UC, rheumatoid arthritis, psoriasis 
and psoriatic arthritis patients.13-15 Although an overall increase in 
cholesterol and in particular in LDL levels is unwanted, an increase 
in HDL can be beneficial. Therefore, the clinical relevance of these 
changes is presently not clear. In the OCTAVE programme, four 
major adverse cardiovascular events were observed (incidence rate 
0.24 per 100 years of exposure [95% CI 0.07-0.62]), of whom three 
patients had ≥4 cardiovascular risk factors including hyperlipidaemia 
at baseline.16 This incidence rate is similar to that observed in RA.17 
Up to now, no correlation between tofacitinib and cardiovascular 
morbidity and mortality in UC patients has been found, but long-
term data are needed.16
The positioning of novel treatments for UC, and IBD in general, 
is complex and depends on a multitude of variables. Outcomes 
such as efficacy, safety, mode of administration and costs should 
TA B L E  4   Reasons for discontinuation of tofacitinib treatment in 
ulcerative colitis patients
 N = 46 (37.4%)
Treatment duration—weeks Median (IQR) 8.5 (6.1-13.5)
Reason discontinuation
No response N (%) 35 (76.1)
Loss of response N (%) 3 (6.5)
Adverse events N (%) 7 (15.2)
At request of patient N (%) 1 (2.2)
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all be considered before selecting a treatment option for an individ-
ual patient. Tofacitinib differs from recently approved biologicals 
for UC, such as vedolizumab and ustekinumab, with respect to its 
mode of administration (oral vs intravenous or subcutaneous) and 
the short induction period with potential rapid clinical response to 
treatment.18 In accordance with other treatments, prior failure to 
biological treatment is an important negative predictor to response. 
In our cohort, vedolizumab therapy was associated with a signifi-
cantly lower corticosteroid-free clinical remission rate at week 24 in 
multivariable analysis (OR: 0.327 95% CI: 0.114-0.938, P = 0.038). 
Whether this reflects the selection of refractory patients, or an im-
pact on the responsiveness of the inflammatory condition to sub-
sequent therapies, remains to be determined. To further establish 
the treatment algorithm for UC, head-to-head trials are needed in 
patients both prior to, but also after anti-TNF failure.
The strength of this study lies in the systematic prospective fol-
low-up with pre-defined clinically relevant endpoints and the sub-
stantial cohort size since all patients initiating tofacitinib in regular 
care in the 15 participating hospitals were included. Due to the bal-
anced participation of academic (n:8) and non-academic hospitals 
(n:7) and the patient characteristics of our cohort (anti-TNF and 
vedolizumab experienced), our data reflect daily practice that justi-
fies generalisability. Our study has some limitations. As endoscopic 
evaluation was not mandatory and often performed when mucosal 
inflammation was expected, a substantial bias would have been in-
troduced when these data were presented. To limit this bias we only 
analysed endoscopic results of centres with systematic endoscopic 
follow-up regardless of disease activity, resulting in a limited num-
ber of patients available for endoscopic analysis. There was no man-
datory adjudication process to determine the drug-related adverse 
events. The relation to treatment was based on physician assessment 
and it is therefore possible that causality of adverse events was sub-
jective. The effect of tofacitinib on lipid profile was measured in a 
subset of patients. The evaluation of the lipid profile was not part 
of standard IBD care in the Netherlands before the introduction of 
tofacitinib and this assessment was not fully implemented in daily 
practice at the start of our study. With increasing experience of to-
facitinib prescription in UC, we expect the number of patients with 
systematic lipid evaluations to increase over time. Finally, although 
this is the largest cohort of tofacitinib to date, the follow-up period is 
relatively short and long-term follow-up is required to further evalu-
ate the safety profile.
To conclude, this real-world study shows that tofacitinib is an 
effective treatment in 29% of this therapy-refractory cohort of UC 
patients after 24 weeks of treatment. A substantial proportion of 
patients experienced adverse events leading to treatment discontin-
uation in 6% of patients. No thromboembolic events were observed 
in this relatively short follow-up period. Prior failure to vedoli-
zumab treatment was associated with a reduced clinical remission 
rate. Further studies are needed to investigate whether this finding 
merely represents a refractory UC population or whether this is due 
to a change in the inflammatory profile, to adequately position tofac-
itinib in the expanding field of treatment options for UC.
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